Table 1.
Basic characteristics and quality evaluation of literaturs.
| Disease | Author, year | Cases T/C | Diagnostic standard | Age (years) range, mean | Sex male/female |
||
|---|---|---|---|---|---|---|---|
| Depressed | Meng and Zhang, 2020 | 35/35 | CCMD-2&CDEES&HAMD | T; 29∼77, 53.18 ± 8.16 | C; 29∼78, 53.75 ± 8.25 | T; 21/14 | C; 20/15 |
| Duan et al., 2020 | 38/38 | HAMD | T; 49∼59, 53.53 ± 2.12 | C; 48∼58, 53.21 ± 2.18 | NR | NR | |
| Zhang et al., 2019 | 44/44 | HAMD&NIHSS&QOL-100 | T; 54∼79, 64.12 ± 2.46 | C; 53∼79, 64.12 ± 2.46 | T; 29/15 | C; 28/16 | |
| Guo et al., 2016 | 43/43 | KMI&HAMD&psychiatry&GCM | T; 40∼55, 39.5 ± 6.0 | C; 42∼55, 38.4 ± 7.2 | NR | NR | |
| Wang et al., 2014 | 60/40 | HADS | NR | NR | NR | NR | |
| Yin et al., 2014 | 18/18 | HAMD | NR | NR | NR | NR | |
| Li and Gao, 2014 | 34/34 | CMD&CCMD-3 | T; 35∼70, 51.2 ± 3.5 | C; 35∼70, 51.2 ± 3.5 | T; 20/14 | C; 18/16 | |
| Tang and Bu, 2012 | 26/26 | NIHSS | NR | NR | NR | NR | |
| Miu et al., 2012 | 19/19 | HAMD | T; 72.6 ± 13.2 | C; 73.3 ± 12.7 | T; 6/13 | C; 7/12 | |
| Nie et al., 2010 | 33/29 | HAMD | T; 65∼84 | C; 63∼85 | T; 14/19 | C; 16/14 | |
| Chen et al., 2004 | 40/39 | HAMD&AFI | NR | NR | NR | NR | |
| Wang et al., 2015 | 30/30 | HAMD&KMI | NR | NR | NR | NR | |
| Wen et al., 2018 | 31/32 | HAMD | T; 61∼83, 71.7 ± 4.7 | C; 60∼83, 71.2 ± 4.6 | T; 18/14 | C; 17/17 | |
|
| |||||||
| Menopausal syndrome | Xie et al., 2020 | 30/30 | AFG&IMCM | Y; 63.87 ± 8.05 | C; 63.77 ± 2.404 | — | |
| Han and Wan, 2020 | 67/66 | OG&GDTCGDTCM | T; 45∼55, 50.27 ± 6.35 | C; 45∼55, 50.64 ± 6.58 | |||
| Shen et al., 2019 | 50/50 | NR | T; 43∼55, 44 ± 8 | C; 40∼55, 45 ± 10 | |||
| Song et al., 2018 | 30/30 | GPTTDC&HAMD&CDTE&GPCRNCM | T; 40∼60, 50 ± 3.8 | C; 45∼55, 49 ± 4.1 | |||
| Zhou et al., 2015 | 86/86 | NR | T; 42∼53, 45.27 ± 10.12 | C; 43–55, 43.78 ± 11.65 | |||
| Zhang et al., 2012 | 27/27 | DSM&PCMP | T; 43∼54, 46.5 ± 6.3 | C; 44∼55, 45.3 ± 7.2 | |||
|
| |||||||
| Insomnia | Guan et al., 2020 | 36/36 | HAMD&PSQI&ASRSA | T; 42∼65, 49.7 ± 6.4 | C; 41∼65, 49.4 ± 6.8 | T; 17/19 | C; 16/20 |
| Li et al., 2019 | 27/29 | CCMD-3&GPCRNCM | T; 51.85 ± 7.49 | C; 52.03 ± 7.10 | T; 12/15 | C; 12/17 | |
| Zhang et al., 2019 | 32/30 | CCCMD&GPCRNCM&RPTITSD | T; 30∼55, 41.2 ± 3.6 | C; 30∼55, 40.8 ± 4.1 | T; 15/17 | C; 14/16 | |
| Guo et al., 2019 | 33/33 | CDTE | T; 62∼79 66.52 ± 1.11 | C; 60∼78 66.23 ± 1.25 | T; 14/19 | C; 15/18 | |
| Zhao and Yuan, 2019 | 32/32 | NR | T; 51∼87 68.42 ± 0.25 | C; 50∼88 68.39 ± 0.57 | T; 17/15 | C; 18/14 | |
| Xin et al., 2018 | 30/30 | CDCMDC&CJCTCM | T; 42.2 ± 6.54 | C; 40.7 ± 4.95 | T; 12/18 | C; 11/19 | |
| Zhang et al., 2018 | 96/96 | Endocrinology&CCMD | T; 46∼56 | C; 43∼58 | NR | NR | |
| Wang et al., 2015 | 60/60 | CCMD-3 | NR | NR | NR | NR | |
| Qu and Sun, 2019 | 51/41 | urosurgery&IMCM | T; 32∼80, 54.1 ± 3.3 | C; 29∼74, 57.4 ± 2.7 | T; 36/24 | C; 35/25 | |
| Li et al., 2014 | 18/18 | CDTE | T; 66.5 ± 5.6 | C; 67.1 ± 5.3 | T; 7/11 | C; 6/12 | |
| Wang et al., 2008 | 65/55 | CCMD&HAMD&CDTEIM | NR | NR | T; 34/31 | C; 23/32 | |
| Pan et al., 2015 | 38/36 | CCCMD | T; 36∼47, 42.73 ± 4.27 | C; 38∼48, 43.64 ± 3.76 | NR | NR | |
| Zhang et al., 2015 | 36/36 | OG&CCMD | T; 49.7 ± 6.4 | T; 69.4 ± 6.8 | NR | NR | |
Note: CCMD, chinese classification of mental disorders; CCMD-2, chinese classification of mental disorders vertion 2; CCMD-3, chinese classification of mental disorders vertion 3; CDEES, criteria for diagnosis and efficacy evaluation of stroke; HAMD, hamilton depression scale; NIHSS, national institutes of health stroke scale; QOL-100, quality of life-100; KMI, kupperman; GCM, gynecology of Chinese medicine; HADS, hospital anxiety and depression scale; CMD, chinese medicine diagnostics; AFI, assessment of functional impairment; AFG, atrial fibrillation guide vertion 2014; IMCM, internal medicine of chinese medicine; OG, obstetrics and gynecology; GDTCGDTCM, guidelines for the diagnosis and treatment of common gynecological diseases in traditional Chinese medicine; GPTTDC, guidelines for prevention and treatment of type 2 diabetes in china vertion 2013; CDTE, criteria for diagnosis and therapeutic effect; GPCRNCM, guiding principles for clinical research of new chinese medicines; DSM, the diagnostic and statistical manual of mental disorders; PCMP, practical chinese medicine psychiatry; PSQI, pittsburgh sleep quality index; ASRSA, asberg side-effect rating scale for antidepressant; CCCMD, Chinese classification of mental disorders; RPTITSD, research progress in the treatment of insomnia by TCM syndrome differentiation; CDCMDC, classification and diagnostic criteria of mental disorders in China; CJCTCM, classification and judgment of constitution of traditional Chinese medicine; CDTEIM, criteria for diagnosis and therapeutic effect of internal medicine.